There is a point in almost every biologics program when process development starts raising an uncomfortable question: are we still improving the process, or are we simply delaying manufacturing?
It is not an easy distinction.
Moving into GMP manufacturing too early can expose weaknesses that would have been much easier to solve at development scale. But continuing to optimize every parameter can consume time and budget without materially improving the product or reducing manufacturing risk.
For sponsors working with a CDMO, the objective should therefore not be to create a perfect process. It should be to create a process that is sufficiently understood, robust and scalable for the next stage.
A process does not need to be perfect to be ready
Early development naturally generates opportunities for improvement. A different feed strategy might increase expression. Another chromatography condition might improve recovery. A slightly different harvest point could provide cleaner material.
The temptation is to continue.
But optimization has diminishing returns.
An improvement from 0.5 g/L to 2 g/L may fundamentally change manufacturing economics. Moving from 2 g/L to 2.1 g/L probably will not. The same principle applies downstream. Removing an unstable purification step can be strategically important. Increasing recovery by one percentage point may not justify another development cycle.
The useful question is not, “Can we improve this further?”
It is, “Would this improvement change our ability to manufacture the biological product reliably?”
Robustness matters more than a record yield
The highest yield achieved during development is rarely the most useful number.
What matters is whether performance can be reproduced.
A process that delivers exceptional productivity under one narrow set of conditions may prove difficult to execute at manufacturing scale. By contrast, a slightly less productive process with broader operating ranges can offer much greater confidence.
That is why biologics process development should progressively shift from optimization toward understanding.
Which parameters actually affect product quality? Where is the process sensitive? Which steps have sufficient operating margin? What happens when normal manufacturing variability is introduced?
These questions are far more relevant to future GMP manufacturing than the best result obtained in a single experiment.
Your downstream process may decide when development is finished
For recombinant proteins, upstream performance tends to attract attention because expression is easy to measure.
But the final economics depend on recoverable product.
A protein expressed at high levels is not especially valuable if purification results in major losses, problematic impurities or repeated process adjustments.
The relationship between USP and DSP therefore needs to be considered before manufacturing begins. Improving expression can even create new purification problems if the impurity profile changes or downstream operations become overloaded.
Good protein manufacturing development considers the whole process rather than optimizing upstream and downstream in isolation.
Manufacturing equipment should already be part of the conversation
A laboratory process cannot be assessed in isolation from the equipment that will eventually execute it.
Mixing, oxygen transfer, centrifugation, homogenization, filtration and chromatography all behave differently as scale changes.
This does not mean every operation must already be locked. It means that the development process should have a credible route into the intended manufacturing environment.
A useful CDMO partner should therefore challenge development decisions that may create unnecessary difficulty later.
Sometimes the right answer is another development experiment. Sometimes it is moving forward.
Knowing the difference requires scientific judgement rather than a standard development package.
The stopping point depends on what comes next
A process intended to produce a small amount of material for an early study does not require the same maturity as a process approaching validation and commercial supply.
Development should be proportionate to the decision the next batch needs to support.
For an early clinical program, the priority may be reproducible GMP manufacturing and sufficient control of product quality. Later, additional characterization and optimization can build deeper process understanding as the program evolves.
Trying to solve every future problem before the first GMP batch can be just as inefficient as ignoring them altogether.
Development should create momentum, not become a holding pattern
The best process development CDMO does not simply run more experiments.
It helps the sponsor decide which experiments matter.
At 53Biologics, process development is connected with manufacturing, analytical support and final product activities. This allows development decisions to be considered against the equipment, quality framework and next manufacturing stage rather than as isolated R&D exercises.
The goal is not a theoretically perfect process.
It is a process that gives the team enough confidence to make the next decision and keep the program moving.
If you are unsure whether your recombinant protein process needs further development or is ready to progress toward GMP manufacturing, talk to our scientific team. Sometimes the most valuable development decision is knowing when to stop developing.
About 53Biologics:
53Biologics is the end-to-end biologics CDMO built to keep progress moving. We combine scientific expertise, integrated in-house capabilities and a close, hands-on way of working to help biotech teams make confident decisions, adapt as programs evolve and stay with one partner from early development through commercialization. With process development, manufacturing, analytics and fill-finish connected under one system, we reduce handoffs, protect continuity and help clients grow without disruption. We were made for this.
For more information or to speak with one of our experts email us at info@53biologics.com